<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03188900</url>
  </required_header>
  <id_info>
    <org_study_id>SC3455</org_study_id>
    <nct_id>NCT03188900</nct_id>
  </id_info>
  <brief_title>Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia</brief_title>
  <acronym>APHERESE</acronym>
  <official_title>New Therapeutic Strategy Against Preeclampsia: Angiogenic Switch to Physiological State by Extracorporeal Removal of sFlt-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INSERM UMR-S 1139</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to setup a collection of maternal plasma and serum from patients with
      preeclampsia and normal pregnancy for in vitro validation of new therapeutics based on
      extra-corporal removal of sFlt-1
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal
      pregnancy (NP) :

        -  Between 20WG and 23WG+6D : 20 patients with PE and 20 patients with NP

        -  Between 24WG and 27WG+6D : 20 patients with PE and 20 patients with NP

        -  Between 28WG and 31WG+6D : 20 patients with PE and 20 patients with NP

        -  Between 32WG and 35WG+6D : 20 patients with PE and 20 patients with NP

        -  Between 36WG and 40WG+6D : 20 patients with PE and 20 patients with NP
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">April 12, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 12, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>22 Weeks</target_duration>
  <primary_outcome>
    <measure>ratio sFlt-1/PlGF</measure>
    <time_frame>Day 0</time_frame>
    <description>measurement of of sFlT-1 and PlGF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetics of these ratios sFlt-1/PlGF during pregnancy</measure>
    <time_frame>until 5 month</time_frame>
    <description>measurement of of sFlT-1 and PlGF at many times</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>preeclampsia</arm_group_label>
    <description>pregnancy with preeclampsia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>pregnancy without preeclampsia</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A collection of maternal plasma and serum</intervention_name>
    <description>A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)</description>
    <arm_group_label>preeclampsia</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        pregnancy with preeclampsia and without preeclampsia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 to 50 years old

          -  Singleton pregnancies between 20 and 41 weeks of gestation

          -  Preeclampsia

          -  Normal pregnancy

        Exclusion Criteria:

          -  Age&lt;18

          -  Infectious disease: HIV, HBV or HCV

          -  Multiple pregnancies

          -  Opposition of the patient
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edouard Lecarpentier, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Intercommunal de Créteil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vassilis Tsatsaris, MD, PhD</last_name>
    <phone>+33 1 58 41 38 71</phone>
    <email>vassilis.tsatsaris@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence Lecomte, PhD</last_name>
    <phone>+33 1 58 41 35 45</phone>
    <email>laurence.lecomte@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vassilis Tsatsaris, MD, PhD</last_name>
      <phone>+33 1 58 41 38 71</phone>
      <email>vassilis.tsatsaris@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab. 2003 Nov;88(11):5555-63.</citation>
    <PMID>14602804</PMID>
  </reference>
  <reference>
    <citation>Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi SA, Wenger J, Lucchesi KJ, Tamez H, Lindner T, Fridman A, Thome U, Kribs A, Danner M, Hamacher S, Mallmann P, Stepan H, Benzing T. Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. J Am Soc Nephrol. 2016 Mar;27(3):903-13. doi: 10.1681/ASN.2015020157. Epub 2015 Sep 24.</citation>
    <PMID>26405111</PMID>
  </reference>
  <reference>
    <citation>Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004 Feb 12;350(7):672-83. Epub 2004 Feb 5.</citation>
    <PMID>14764923</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>apheresis</keyword>
  <keyword>sflt-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

